公开(公告)号：EP2303306A2

公开(公告)日：2011-04-06

申请号：EP09758730.7

申请日：2009-06-02

Applicant: STC.UNM

Inventor： DU CLOS, Terry, W. ,  MOLD, Carolyn

IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

CPC classification number: A61K38/1745 ,  C07K14/4737

Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

公开(公告)号：WO2009148566A2

公开(公告)日：2009-12-10

申请号：PCT/US2009/003338

申请日：2009-06-02

Applicant: STC.UNM ,  DU CLOS, Terry, W. ,  MOLD, Carolyn

Inventor： DU CLOS, Terry, W. ,  MOLD, Carolyn

IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

CPC classification number: A61K38/1745 ,  C07K14/4737

Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

Abstract translation: 本发明涉及使用由亮氨酸（Y175L CRP）代替酪氨酸175或用谷氨酸（L176E CRP）代替的亮氨酸176用于治疗与SLE有关的各种疾病状态和病症的突变型CRP分子， 包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的血液学病症，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病，其他如本文另有公开。 在本发明的另一方面，降低与SLE相关的疾病状态或病症发生风险的患者将发生爆发的可能性是本发明的另外的方面。 本发明涉及突变型Y175L CRP或L176E CRP在治疗多发于系统性红斑狼疮SLE继发性疾病状态或病症中的应用。 本发明还涉及免疫性血小板减少性紫癜的治疗。 还公开了基于这些突变CRP分子的药物组合物。